- Home
- UPWK vs GLPG Comparison
UPWK vs GLPG Comparison
Compare UPWK & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UPWK
- GLPG
- Stock Information
- Founded
- UPWK 2013
- GLPG 1999
- Country
- UPWK United States
- GLPG Belgium
- Employees
- UPWK N/A
- GLPG N/A
- Industry
- UPWK EDP Services
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- UPWK Technology
- GLPG Health Care
- Exchange
- UPWK Nasdaq
- GLPG Nasdaq
- Market Cap
- UPWK 2.0B
- GLPG 2.1B
- IPO Year
- UPWK 2018
- GLPG 2005
- Fundamental
- Price
- UPWK $15.94
- GLPG $31.78
- Analyst Decision
- UPWK Buy
- GLPG Hold
- Analyst Count
- UPWK 15
- GLPG 4
- Target Price
- UPWK $19.57
- GLPG $30.00
- AVG Volume (30 Days)
- UPWK 2.1M
- GLPG 229.6K
- Earning Date
- UPWK 11-03-2025
- GLPG 11-05-2025
- Dividend Yield
- UPWK N/A
- GLPG N/A
- EPS Growth
- UPWK 220.06
- GLPG N/A
- EPS
- UPWK 1.72
- GLPG N/A
- Revenue
- UPWK $772,904,000.00
- GLPG $323,674,692.00
- Revenue This Year
- UPWK $2.50
- GLPG $1.77
- Revenue Next Year
- UPWK $5.37
- GLPG $0.44
- P/E Ratio
- UPWK $9.25
- GLPG N/A
- Revenue Growth
- UPWK 3.92
- GLPG 5.43
- 52 Week Low
- UPWK $11.13
- GLPG $22.36
- 52 Week High
- UPWK $20.54
- GLPG $37.78
- Technical
- Relative Strength Index (RSI)
- UPWK 42.65
- GLPG 43.66
- Support Level
- UPWK $15.71
- GLPG $30.92
- Resistance Level
- UPWK $17.85
- GLPG $32.62
- Average True Range (ATR)
- UPWK 0.58
- GLPG 0.84
- MACD
- UPWK -0.08
- GLPG -0.26
- Stochastic Oscillator
- UPWK 10.75
- GLPG 21.08
About UPWK Upwork Inc.
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with skilled independent professionals. The company develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to clients.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.